📋 CDE Peptide Drug Review Guidelines
China's Center for Drug Evaluation (CDE) under the National Medical Products Administration has issued a series of technical guidelines for peptide drug development and review in recent years. This chapter systematically compiles CDE's review requirements, quality control standards, submission guidance, and common review deficiencies, providing actionable direction for registration applications.
1. CDE Technical Guidance Development History
| Release Date |
Guidance Title |
Milestone Significance |
Current Status |
| 2008.08 |
"Technical Guidelines for Synthetic Peptide Drug Pharmaceutical Research (Draft)" |
First peptide pharmaceutical research framework |
Superseded |
| 2018.07 |
"Technical Guidelines for Chemical Peptide Drug Pharmaceutical Research" |
Officially released peptide pharmaceutical guidance |
Current |
| 2019.08 |
"Technical Guidelines for Synthetic Peptide Drug Pharmaceutical Research and Evaluation" |
Refined synthesis process and quality control requirements |
Current |
| 2020.06 |
"Technical Guidelines for Drug Genotoxic Impurity Research" |
Standardized EPC/DPA impurity control |
Current |
| 2021.05 |
"ICH Q3D (R2) Elemental Impurities Guideline" Implementation |
Standardized elemental impurity control for peptide drugs |
Current |
| 2022.03 |
"Technical Guidelines for Drug Impurity Research (Revised)" |
Supplemented special peptide impurity requirements |
Current |
| 2023.05 |
"Technical Guidelines for Peptide Drug Biosimilar Development and Evaluation" |
First recombinant peptide biosimilar guideline |
Current |
| 2024.05 |
"Technical Guidelines for Peptide Drug Quality Control (Trial)" |
Comprehensive quality control baseline finalized |
Current |
| 2025.02 |
"Chemical Drug Registration Classification and Submission Requirements (Revised)" |
Peptide registration classification further clarified |
Current |
| 2025E |
"Technical Guidelines for Synthetic Peptide Continuous Flow Manufacturing Process" (Proposed) |
Continuous flow process review standardization |
Under consultation |
Guideline Evolution Path
CDE's peptide drug guidelines have evolved through three phases:
- Phase 1 (2008–2018): Exploration, focused on pharmaceutical technical framework
- Phase 2 (2018–2023): Refinement, adding specialized guidelines on impurity control, biosimilars, etc.
- Phase 3 (2024–): Maturity, quality control baseline finalized, forward-looking coverage of continuous flow and other novel processes
2. Current Effective Guidelines Overview
| Guidance Title |
Release Date |
Key Content |
Applicable Scope |
| "Technical Guidelines for Peptide Drug Quality Control (Trial)" |
2024.05 |
Peptide API quality control, impurity analysis, stability requirements |
Chemically synthesized peptide drugs |
| "Technical Guidelines for Chemical Peptide Drug Pharmaceutical Research" |
2018 |
Peptide drug synthesis process, structural confirmation, formulation development |
Synthetic peptide new drugs/generics |
| "Technical Guidelines for Synthetic Peptide Drug Pharmaceutical Research and Evaluation" |
2019 |
Synthetic route design, intermediate quality control, process validation |
Synthetic peptide NDA/ANDA |
| "Technical Guidelines for Peptide Drug Biosimilar Development and Evaluation" |
2023 |
Peptide biosimilar comparability studies, clinical bridging |
Recombinant peptide biosimilars |
| "Technical Guidelines for Drug Impurity Research" |
2022 (revised) |
Organic/inorganic impurities, residual solvent limits |
All chemical drugs (including peptides) |
| "Technical Guidelines for Drug Genotoxic Impurity Research" |
2020 |
EPC/DPA and other genotoxic impurity assessment and control |
Synthetic peptides |
3. Key Technical Requirements: Peptide vs. Small Molecule vs. Biologic
| Technical Requirement Dimension |
Peptide Drug |
Small Molecule Chemical Drug |
Biologic (mAb/Protein) |
| Molecular Weight Range |
500–5,000 Da |
<500 Da |
>5,000 Da (typically >150K Da) |
| Manufacturing Method |
Chemical synthesis (SPPS/LPPS) |
Chemical synthesis |
Biological expression (CHO/E. coli, etc.) |
| Structural Confirmation |
MS/MS + Edman + amino acid analysis |
NMR + X-ray + mass spectrometry |
Higher-order structure (X-ray/CD spectroscopy) |
| Impurity Profile Analysis |
EPC/DPA/deletion peptides/oxidized peptides |
By-products/degradants/genotoxic impurities |
Aggregates/fragments/glycosylation variants |
| Purity Requirement |
≥98.0% (GMP grade) |
≥99.0% (new drug) |
≥95.0% (monomer) |
| Stability Challenges |
Hydrolysis/oxidation/disulfide isomerization |
Degradation/photolysis |
Aggregation/unfolding/deamidation |
| Immunogenicity Assessment |
Required for long-acting/recombinant peptides |
Usually not required |
Mandatory (ADA/NAb) |
| BE/Clinical Equivalence |
Short peptides: BE; Long peptides: clinical bridging |
Typically BE sufficient |
Clinical comparability study |
| Originator Consistency Evaluation |
Impurity profile + sequence + polymorph |
Impurity profile + polymorph + dissolution |
Structure + function + PK + immunogenicity |
| Formulation Technical Difficulty |
Medium (microspheres/sustained release challenging) |
Medium |
High (injectable solution stability) |
4. Peptide API Quality Control Indicator Requirements
| Quality Control Item |
Technical Requirement |
Method |
Limit Requirement |
Attention Level |
| Assay (Purity) |
HPLC area normalization method |
RP-HPLC (0.1% TFA/acetonitrile system) |
API ≥98.0% (GMP grade) |
🔴 Critical |
| Related Substances |
Impurity profile analysis (EPC/DPA/deletion/oxidation) |
HPLC-MS |
Single unknown impurity ≤0.5%, total impurities ≤2.0% |
🔴 Critical |
| Amino Acid Composition |
Consistent with theoretical sequence |
Hydrolysis + AAA analysis |
Each amino acid molar ratio ±10% |
🟡 Important |
| Sequence Confirmation |
Edman degradation + MS/MS fragmentation |
N-terminal sequencing / LC-MS/MS |
100% sequence coverage |
🔴 Critical |
| Chiral Purity |
D-amino acid content control |
Chiral HPLC or chiral GC/MS |
D-amino acid ≤0.5% |
🔴 Critical |
| EPC Content |
Epimeric impurity control |
Specific chiral HPLC method |
≤0.5% recommended (per EPC) |
🔴 Critical |
| DPA Content |
Deletion peptide impurity control |
HPLC-MS |
≤1.0% recommended |
🔴 Critical |
| Oxidation Impurities |
Met/Trp/Cys oxidation products |
HPLC-MS |
≤1.0% recommended |
🟡 Important |
| Residual Solvents |
Per ICH Q3C classification |
GC headspace |
Class 1/2/3 respective limits |
🟡 Important |
| Elemental Impurities |
Per ICH Q3D classification |
ICP-MS |
Per route-of-administration limits |
🟡 Important |
| Water Content |
Residual moisture control |
Karl Fischer |
≤5.0% (API) |
🟢 General |
| Heavy Metals |
Per ChP General Chapters |
ICP-MS |
Lead ≤2 ppm, Cadmium ≤1 ppm, Mercury ≤1 ppm |
🟡 Important |
| Bacterial Endotoxins |
Per ChP General Chapters |
LAL test |
Per injection requirements |
🔴 Critical |
| Microbial Limits |
Per ChP General Chapters |
Membrane filtration |
Non-sterile ≤100 CFU/g |
🟡 Important |
| Peptide Content |
Percentage of theoretical value |
UV quantitation / nitrogen determination |
95.0–105.0% |
🟡 Important |
| Disulfide Bond Connectivity |
Disulfide linkage confirmation |
Non-reducing digestion + MS |
Consistent with theoretical connectivity |
🔴 Critical (Cys-containing) |
| Solid-State Morphology |
Polymorph/amorphous characterization |
XRPD/DSC/TGA |
Record morphological characteristics |
🟢 General (consistency) |
| Specific Optical Rotation |
Optical activity control |
Polarimeter |
Product-specific limits |
🟢 General |
Special EPC/DPA Impurity Control Requirements
CDE has required since 2022 that synthetic peptides must address EPC (epimeric peptide contaminants) and DPA (deletion peptide impurities) control. Recommended EPC limit: ≤0.5%. Recommended DPA limit: ≤1.0%. For complex peptides with multiple chiral centers, complete chiral impurity characterization data must be submitted. The 2024 Quality Control Guidelines further emphasize EPC/DPA identification and limit-setting methods.
5. Registration Classification and Submission Requirements
Peptide New Drug (Class 1)
| Module |
Content Requirements |
Key Points |
| Module 1 |
Administrative documents and drug information |
Indication selection rationale, benefit-risk assessment |
| Module 2 |
Summaries (pharmaceutical/pharmacology/toxicology/clinical) |
Peptide structure-activity relationship (SAR) analysis |
| Module 3 |
Pharmaceutical research data |
Detailed synthesis process, full structural confirmation spectra, impurity profile analysis |
| Module 4 |
Pharmacology and toxicology data |
Safety pharmacology, repeat-dose toxicity, immunogenicity evaluation |
| Module 5 |
Clinical study data |
Dose exploration, PK/PD, efficacy confirmation trials |
Peptide Generic Drug (Class 4)
| Module |
Content Requirements |
Difference from Innovative Drug |
| Module 1–2 |
Same as innovative drug |
— |
| Module 3 |
Pharmaceutical comparability study |
Impurity profile and MS/MS comparison with originator required |
| Module 4 |
Toxicology + BE/Clinical |
Some toxicology may be exempted; BE or clinical equivalence required |
| Module 5 |
Simplified clinical |
Typically only BE (short half-life peptides) or equivalence study |
Submission Document Checklist
| No. |
Document Item |
Mandatory |
Special Peptide Requirements |
| M1 |
Drug Registration Application Form |
✅ Required |
Specify peptide category |
| M2 |
Manufacturing Process Data |
✅ Required |
Synthetic route map + intermediate quality control at each step |
| M3 |
Structural Confirmation Data |
✅ Required |
Full MS/MS sequence coverage + amino acid analysis |
| M4 |
Quality Study Data |
✅ Required |
EPC/DPA impurity special study |
| M5 |
Stability Study Data |
✅ Required |
Accelerated 6 months + long-term 36 months |
| M6 |
API/Formulation Quality Standards |
✅ Required |
HPLC method validation data |
| M7 |
Pharmacodynamic Study Data |
Depending on registration class |
Peptide-specific binding/activity data |
| M8 |
Pharmacokinetic Study |
Depending on registration class |
Metabolic stability / metabolite identification |
| M9 |
Toxicology Study Data |
Depending on registration class |
Peptide-specific immunogenicity evaluation |
| M10 |
Clinical Study Protocol/Report |
Depending on registration class |
BE equivalence design considerations |
| M11 |
Originator Reference / Reference Product Data |
Required for generics |
Source/batch/comparison data |
| M12 |
Packaging Materials and Container Data |
✅ Required |
Adsorption study (peptides prone to adsorption) |
| M13 |
Sample Test Report |
✅ Required |
Three consecutive validation batches data |
| M14 |
Foreign Document Translation |
Where applicable |
Ensure terminology accuracy |
6. Peptide Generic Consistency Evaluation Key Points
| Evaluation Dimension |
Key Requirements |
Acceptance Criteria |
| Structural Identity |
Primary sequence confirmation, disulfide bonding, post-translational modification |
Fully consistent with originator |
| Impurity Profile Identity |
EPC/DPA/oxidation impurities/aggregate comparison |
Impurity types and ratios consistent with originator |
| Polymorph/Solid-State Morphology |
Peptide API solid-state characterization (XRPD/DSC) |
Solid-state morphology consistent with originator |
| Formulation Quality Attributes |
Release profile (for sustained-release), particle size |
f2 factor ≥50 |
| Stability |
Accelerated/long-term stability |
Not inferior to originator |
| Immunogenicity Assessment |
Where applicable (recombinant peptides) |
Antibody incidence not exceeding originator |
7. Top 10 Common Review Deficiencies
| Rank |
Deficiency Type |
Products Affected |
Frequency |
Typical Issue Description |
| 1 |
Inadequate Impurity Control |
Synthetic peptide new drugs/generics |
⭐⭐⭐⭐⭐ |
EPC/DPA impurities not fully identified or quantified; lack of chiral impurity control methods |
| 2 |
Insufficient Process Validation Data |
Synthetic peptide new drugs |
⭐⭐⭐⭐ |
Inadequate rationale for critical process parameter (CPP) determination; insufficient validation batches |
| 3 |
Incomplete Stability Data |
All peptide products |
⭐⭐⭐⭐ |
Long-term stability data not covering shelf life; incomplete degradation product identification |
| 4 |
Incomplete Structural Confirmation |
Synthetic peptide generics |
⭐⭐⭐⭐ |
MS/MS coverage less than 100%; amino acid analysis deviation exceeding ±10% |
| 5 |
Insufficient Reference Product Comparison |
Peptide generics |
⭐⭐⭐ |
Missing source/batch information for reference product; insufficient batch-to-batch consistency data |
| 6 |
Insufficient Analytical Method Validation |
All peptide products |
⭐⭐⭐ |
HPLC method specificity inadequate (EPC/DPA not fully resolved); LOQ not meeting standards |
| 7 |
BE/Clinical Equivalence Design Flaws |
Peptide generics |
⭐⭐⭐ |
Long-chain peptides blindly adopting BE design without considering PK nonlinearity |
| 8 |
Missing API Physicochemical Characterization |
New drugs/generics |
⭐⭐ |
Basic data missing: hygroscopicity/solubility/pH-solubility profile |
| 9 |
Incomplete Residual Solvent / Elemental Impurity Reporting |
All peptide products |
⭐⭐ |
ICH Q3C/Q3D incompletely executed; not covering all potential residual solvents |
| 10 |
Insufficient Formulation Development |
Injectable peptides |
⭐⭐ |
Inadequate excipient selection rationale; peptide adsorption study missing |
Practical Tips to Avoid Review Deficiencies
- Impurity control upfront: Establish EPC/DPA control strategy at the IND stage to avoid NDA phase supplementary data requests
- Comprehensive reference product characterization: Select at least 3 different batches of reference product for impurity profile comparison
- Full analytical method validation: Ensure HPLC method can effectively separate all known impurities (including EPC diastereomers)
- Allow sufficient stability time: Submit at least 12 months of long-term stability data at NDA filing
- CDE communication strategy: Focus Pre-NDA meeting discussions on impurity control and BE plan
8. Review Communication Mechanism
| Communication Method |
Applicable Phase |
Content |
Timeline |
| Pre-IND Communication |
Before IND submission |
Preclinical study plan, CMC strategy |
60 working days |
| Pre-NDA Communication |
Before NDA submission |
Document completeness, review focus points |
90 working days |
| Phase III Pre-Initiation Communication |
Before Phase III start |
Key clinical endpoint confirmation |
60 working days |
| Deficiency Response Communication |
Under review |
Clarification of supplementary data requirements |
30 working days |
CDE Communication Strategy Recommendations
- Proactive Pre-IND engagement: Given the complexity of peptide drug processes, discussing CMC strategy with CDE before IND significantly reduces the probability of deficiency letters
- Dedicated impurity control discussion: For challenging areas like EPC/DPA, submit a dedicated impurity control strategy
- Leverage overseas clinical trial data: Reference ICH E5/E17 guidelines in registration strategy to accelerate China market entry using foreign data
- Review precedent products: Study review reports and deficiency records of similar previously approved peptide products
Regulatory Basis: Original text of each guideline published on the CDE website, "Drug Registration Management Measures" (2020), "Good Manufacturing Practice for Drugs" (GMP). The above serves as general guidance; specific products require tailored R&D plans based on product characteristics and registration strategy. For peptide drug IND/NDA registration, CMC document preparation, impurity control strategy development, or CDE communication strategy support — contact the drug registration consulting services for professional regulatory consulting and comprehensive peptide drug review guideline interpretation.